Head-To-Head Contrast: Pola Orbis (OTCMKTS:PORBF) versus Eisai (OTCMKTS:ESALY)

Eisai (OTCMKTS:ESALY) and Pola Orbis (OTCMKTS:PORBF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Risk and Volatility

Eisai has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Pola Orbis has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Earnings and Valuation

This table compares Eisai and Pola Orbis’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eisai	$6.74 billion	2.62	$426.79 million	$0.87	70.70
Pola Orbis	$1.24 billion	N/A	$68.62 million	$0.32	29.69

Eisai has higher revenue and earnings than Pola Orbis. Pola Orbis is trading at a lower price-to-earnings ratio than Eisai, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eisai and Pola Orbis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eisai	4.11%	3.86%	2.50%
Pola Orbis	5.92%	7.66%	6.37%

Analyst Recommendations

This is a breakdown of current ratings for Eisai and Pola Orbis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eisai	0	0	0	0	N/A
Pola Orbis	0	0	0	0	N/A

Insider & Institutional Ownership

0.0% of Eisai shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Eisai beats Pola Orbis on 5 of the 9 factors compared between the two stocks.

About Eisai

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

About Pola Orbis

Pola Orbis Holdings Inc., through its subsidiaries, develops, manufactures, and sells cosmetics and related products in Japan and internationally. It operates through Beauty Care and Real Estate segments. The Beauty Care segment offers cosmetics; skincare products; health foods; and fashion products, such as women's underwear, women's apparel, and jewelry under the POLA, ORBIS, Jurlique, H2O PLUS, THREE, DECENCIA, Amplitude, ITRIM, FIVEISM × THREE, and FUJIMI brand names. The Real Estate segment is involved in the leasing of office buildings and residential properties. The company also involves in the management and operation of buildings. It sells its products through department, directly operated retail, duty-free stores, Internet, and cosmetics stores, as well as through door-to-door sales, and mail-order sales. Pola Orbis Holdings Inc. was founded in 1929 and is headquartered in Tokyo, Japan.